OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Sees Significant Increase in Short Interest

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 159,454 shares, a growth of 212.9% from the December 31st total of 50,958 shares. Currently, 0.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 286,690 shares, the days-to-cover ratio is presently 0.6 days. Based on an average daily trading volume, of 286,690 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.7% of the shares of the stock are short sold.

OKYO Pharma Price Performance

Shares of NASDAQ:OKYO traded up $0.01 on Friday, reaching $2.05. The company had a trading volume of 284,507 shares, compared to its average volume of 322,349. The stock has a 50-day moving average price of $2.13 and a 200 day moving average price of $2.32. OKYO Pharma has a twelve month low of $1.01 and a twelve month high of $3.35.

OKYO Pharma (NASDAQ:OKYO) last issued its quarterly earnings results on Friday, January 30th. The company reported ($2.28) EPS for the quarter. On average, equities research analysts predict that OKYO Pharma will post -0.17 EPS for the current fiscal year.

Institutional Investors Weigh In On OKYO Pharma

A hedge fund recently bought a new stake in OKYO Pharma stock. Citadel Advisors LLC purchased a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 15,355 shares of the company’s stock, valued at approximately $31,000. 2.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on OKYO. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of OKYO Pharma in a research report on Thursday. B. Riley began coverage on shares of OKYO Pharma in a research report on Monday, December 8th. They set a “buy” rating and a $5.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of OKYO Pharma in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, OKYO Pharma presently has an average rating of “Hold” and a consensus price target of $6.00.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.